Using proteomics as a powerful tool to develop a vaccine against Mediterranean visceral leishmaniasis
- 77 Downloads
Visceral leishmaniasis (VL) is a tropical infectious disease, which is called Mediterranean visceral leishmaniasis (MVL) in the Mediterranean area. In spite of many attempts, no effective commercial vaccine exists for MVL. To find new targets for developing antileishmanial vaccines, knowing parasite antigens that provoke the immune system are on demand. Nowadays, proteomics methods are defined as approaches for analysis of protein profiling of different cells. Within this framework, detection of new antigens is becoming more facilitated. In this review, we aimed to introduce possible targets using proteomics so; they could be used as candidates for developing vaccines against MVL. It can shed new light in the near future on the development of promising vaccines for MVL.
KeywordsMediterranean visceral leishmaniasis Proteomics Vaccine target
This article was supported by Shiraz University of Medical Sciences under the Grant Number 94-7597.
Sajad Rashidi: Data collection and manuscript writing; Kurosh kalantar: Project development, manuscript editing, and data analysis; Hatam Gholamreza: Project development, manuscript editing.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interests.
- Bhattacharya P, Dey R, Dagur PK, Kruhlak M, Ismail N, Debrabant A et al (2015) Genetically modified live attenuated Leishmania donovani parasites induce innate immunity through classical activation of macrophages that direct the Th1 response in mice. Infect Immun 83:3800–3815CrossRefPubMedPubMedCentralGoogle Scholar
- Fakhar M, Asgari Q, Motazedian M, Mohebali M, Hatam G, Alborzi A (2006) First report of Kala-azar from Qeshm Island in Persian Gulf. Iran J Parasitol 1:53–56Google Scholar
- Gannavaram S, Dey R, Avishek K, Selvapandiyan A, Salotra P, Nakhasi HL (2014) Biomarkers of safety and immune protection for genetically modified live attenuated Leishmania vaccines against visceral leishmaniasis–discovery and implications. Front Immunol 5:241CrossRefPubMedPubMedCentralGoogle Scholar
- Gupta G, Oghumu S, Satoskar AR (2013) Mechanisms of immune evasion in leishmaniasis. Adv Appl Microbiol 82:155–184. https://doi.org/10.1016/B978-0-12-407679-2.00005-3 CrossRefPubMedPubMedCentralGoogle Scholar
- Gupta R, Kumar V, Kushawaha PK, Tripathi ChP, Joshi S, Sahasrabuddhe AA et al (2014) Characterization of glycolytic enzymes-rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis. PLoS ONE 9(1):e86073. https://doi.org/10.1371/journal.pone.0086073 CrossRefPubMedPubMedCentralGoogle Scholar
- Jaiswal A, Khare P, Joshi S, Kushawaha P, Sundar S (2014) Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis. PLoS ONE 9(9):e108556. https://doi.org/10.1371/journal.pone.0108556 CrossRefPubMedPubMedCentralGoogle Scholar
- Kamoun-Essghaier S, Guizani I, Strub JM, Van Dorsselaer A, Mabrouk K, Ouelhazi L et al (2005) Proteomic approach for characterization of immunodominant membrane-associated 30-to 36-kilodalton fraction antigens of Leishmania infantum promastigotes, reacting with sera from mediterranean visceral leishmaniasis patients. Clin Diagn Lab Immunol 12(2):310–320. https://doi.org/10.1128/cdli.12.2.310-320.2005 PubMedPubMedCentralCrossRefGoogle Scholar
- Kushawaha PK, Gupta R, Sundar S, Sahasrabuddhe AA, Dube A (2011) Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge. J Immunol 187:6417–6427CrossRefPubMedGoogle Scholar
- Lewandowicz A, Bakun M, Imiela J, Dadlez M, Specjalistyczny MS, Mas ŚLS (2009) Proteomics in uronephrology new perspectives of noninvasive diagnostics? Nefrol Dial Pol 13:15–21Google Scholar
- Petitdidier E, Pagniez J, Papierok G, Vincendeau P, Lemesre J-L, Bras-Gonçalves R (2016) Recombinant forms of Leishmania amazonensis excreted/secreted promastigote surface antigen (PSA) induce protective immune responses in dogs. PLoS Negl Trop Dis 10(5):e0004614. https://doi.org/10.1371/journal.pntd.0004614 CrossRefPubMedPubMedCentralGoogle Scholar
- Rassi Y, Azizi K, Motazedian M, Javadian E, Rafizadeh S, Fakhar M et al (2007) The seminested PCR based detection of Leishmania infantum infection in asymptomatic dogs in a new endemic focus of visceral leishmaniasis in Iran. J Arthropod Borne Dis 1:38–42Google Scholar
- Tripathi P, Singh V, Naik S (2007) Immune response to Leishmania: paradox rather than paradigm. FEMS Microbiol Rev 51:229–242Google Scholar